SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

October 2025

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x                                 Form 40-F   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

 

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

 

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨                                 No   x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

 

 


 

 

EXHIBITS

 

Exhibit

Number

  

Description of Exhibits

 

 

 

99.1


Intimation dated October 24, 2025

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

 

 

 

 

Date: October 24, 2025

By:

/s/ K Randhir Singh

 

 

Name:

K Randhir Singh

 

 

Title:

Company Secretary

 

3


Exhibit 99.1

 

Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:       + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email: mail@drreddys.com

Web:   www.drreddys.com

 

October 24, 2025

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/Madam,

 

Sub: Update on Senior Management Personnel

 

This is in furtherance to our letter dated September 1, 2025, wherein we had informed that Ms. Archana Bhaskar has resigned from the position of Chief Human Resources Officer (“CHRO”) of the Company, effective from the close of business hours on November 30, 2025.

 

We wish to inform that basis the recommendation of Nomination, Governance and Compensation Committee, the Board of Directors of the Company, at their meeting held today, i.e., October 24, 2025, have assigned additional responsibilities of CHRO’s office to Mr. Sanjay Sharma, Global Head Operations, and a Senior Management Personnel of the Company, effective from December 1, 2025.

 

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are given in the Annexure enclosed herewith.

 

The Board Meeting commenced at 2:00 PM (IST) and concluded at 3:57 PM (IST).

 

This is for your information and records.

 

Thanking you.

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited


K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

 

Encl: as above

 


Annexure

 

Sl. No.

Particulars

Details

1

Reason for change viz. appointment, re-appointment, resignation, removal, death
or otherwise;

The Board has assigned additional responsibilities of CHRO’s office to Mr. Sanjay Sharma, Global Head Operations and a Senior Management Personnel of the Company.

 

2

Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment

December 1, 2025

3

Brief profile (in case of appointment)

Mr. Sharma is a transformational leader with close to 34 years in the FMCG & Pharmaceuticals industry handling diverse set of roles spanning across Manufacturing, Supply Chain, Sales, ESG and Business Transformation in both emerging and developed markets. Sanjay holds a bachelor’s degree in chemical engineering from IIT Delhi, and Advanced Management Program (AMP) from Harvard Business School.

 

4

Disclosure of relationships between directors (in case of appointment of a director)

Not applicable